• The Cigna Group recently announced that long-time CEO David M. Cordani will retire as chief executive officer on July 1, 2026, shifting to executive chair of the board while current president and chief operating officer Brian Evanko takes over as CEO and joins the board.
• This planned leadership handover concentrates operational and boardroom influence in a tight Cordani–Evanko partnership, raising important questions about continuity, governance balance, and execution across Cigna Healthcare and Evernorth Health Services.
• We’ll now examine how the planned transition from David Cordani to Brian Evanko as CEO could reshape Cigna’s broader investment narrative.

Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge.

Cigna Group Investment Narrative Recap

To own Cigna Group, you need to believe its integrated insurance and Evernorth Health Services model can keep generating attractive cash flows despite pressure on pharmacy benefits and medical cost trends. The CEO transition to Brian Evanko, with David Cordani moving to executive chair, does not materially change the near term focus on executing the shift toward rebate free pharmacy models, where the biggest current risk is potential margin pressure and regulatory scrutiny of PBM practices.

The most relevant recent announcement alongside the leadership news is Cigna’s reaffirmation of its 2026 adjusted income from operations outlook, following 10.4% year on year revenue growth in 2025 and a dividend increase to US$1.56 per share. That combination keeps attention on whether Cigna can manage the move toward transparent pharmacy pricing while preserving profitability in Evernorth, which is central to the bull case but also where transition risks are most concentrated.

Yet beneath the orderly leadership handover, investors should be aware of how concentrated exposure to evolving PBM regulation could...

Cigna Group's narrative projects $299.7 billion revenue and $7.8 billion earnings by 2028. This requires 4.6% yearly revenue growth and about a $2.8 billion earnings increase from $5.0 billion today.

Uncover how Cigna Group's forecasts yield a $336.67 fair value, a 29% upside to its current price.

Exploring Other Perspectives

Nine members of the Simply Wall St Community currently see Cigna’s fair value between US$310 and about US$850 per share, showing how far opinions can stretch. Set that against the central risk that tighter oversight of PBM practices and pricing could weigh on Evernorth and, by extension, the group’s longer term earnings resilience.

Explore 9 other fair value estimates on Cigna Group - why the stock might be worth just $310.07!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Cigna Group research is our analysis highlighting 6 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Cigna Group research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cigna Group's overall financial health at a glance.

Searching For A Fresh Perspective?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• The future of work is here. Discover the 28 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Uncover the next big thing with 33 elite penny stocks that balance risk and reward.
• Capitalize on the AI infrastructure supercycle with our selection of the 34 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.